NEW YORK, Sept. 1 /PRNewswire-FirstCall/ -- Pfizer Inc said today that
a federal court in the Middle District of North Carolina has upheld the
company's U.S. patent covering amlodipine besylate, the active ingredient
in Norvasc, the world's most-prescribed branded medicine for treating
hypertension. The patent had been challenged by the generic manufacturer,
Synthon Pharmaceuticals.
Judge James A. Beaty ruled that the patent (U.S. Patent No. 4,879,303)
covering amlodipine besylate is valid and infringed by the generic
manufacturer's product. The decision, which is subject to appeal, prohibits
Synthon from launching a generic version of amlodipine until September
2007.
"The court has affirmed the validity of our Norvasc patent. We will
continue to defend against any patent challenges that seek to undermine the
incentives established for bringing innovative medicines to patients," said
Allen Waxman, Pfizer's general counsel. In January 2006, the same Norvasc
patent was held valid and infringed by Apotex in a decision by the Northern
District Court of Illinois.
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888./ /Company News On-Call:
http://www.prnewswire.com/comp/688250.html
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html /
CONTACT:
Bryant Haskins of Pfizer Inc, +1-212-733-8719
|
